HPS Pharmacies wish to give notice that Fresenius Kabi is anticipating a supply interruption for Fresofol® ampoules as follows:
Fresofol® 1% MCT/LCT Ampoules
Normal supplies are expected to return in mid-May 2021. During this period, Fresofol® 1% LCT 200mg/20mL ampoules will be available. Both of these products contain the same active ingredient, propofol. However, the LCT product is formulated using a long chain triglyceride base while the MCT/LCT product consists of medium chain triglycerides and a long chain triglyceride. Other than the difference in lipid base, the formulas are identical.1
It should be noted that there are differences in the approved indications of these two products. Please consult the relevant product information for details.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Fresenius Kabi on (02) 9391 5555 or your pharmacist at HPS Pharmacies.
Bermingham D. Change to Fresenius Kabi Fresofol Product Range [letter]. Fresenius Kabi, 2020.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates